U.S. Healthtech Stock News

On August 12, 2025, Pharvaris N.V. reported its second quarter and six-month financial results, revealing a net loss of €45.48 million and €91.82 million, respectively, both higher than the same periods last year. The company’s losses per share from continuing operations also increased significantly year-over-year, indicating ongoing financial pressures. With widening losses driving recent earnings headlines, we’ll explore how this shapes Pharvaris’s investment narrative amid persistent cost...

Despite an already strong run, Twin Disc, Incorporated ( NASDAQ:TWIN ) shares have been powering on, with a gain of 40...

If you are wondering what to do with HubSpot stock right now, you are in good company. Investors have been on a wild ride lately, with the stock climbing 4.4% over the past week, yet still sitting nearly 33% lower year-to-date. That kind of volatility can stir up lots of questions, especially when you realize that just in the last five years, HubSpot has delivered returns over 56%. Clearly, the story here is more complex than a single quarter or market shift. Part of that story comes down to...

Thinking about what to do with Constellation Energy stock? You are not alone. With so much movement in the market, it can be tough to know when to sit tight and when to take action. Lately, Constellation Energy has given investors a lot to talk about. Over the last week, the stock dipped 3.7%, and in the past month, it slid by 5.1%. If you zoom out, the story becomes more interesting. Shares are still up a notable 28.1% year-to-date, and an impressive 60.4% over the past 12 months. Looking...

Thinking about what to do with Biogen stock right now? You are not alone. There's a lot of debate swirling around this biotech giant, especially as its shares have been through quite the journey over the past few years. Some investors have been disappointed by the slide—down over 33.4% in the past year and more than 50% in the last five years—while others are starting to pay attention to signs that sentiment could be shifting. Over the last week, Biogen stock crept up a modest 0.3%, with a...

If you have been following Webull lately, you probably noticed the buzz in the investment community. Many investors are watching closely, trying to decide whether to double down or take profits now that the stock has had such a dynamic ride. Webull's story is hard to ignore. After climbing an impressive 28.7% since the start of the year and delivering a strong 33.3% gain over the past twelve months, expectations are running high. Despite those impressive long-term returns, the last month has...

Most readers would already be aware that Cabot's (NYSE:CBT) stock increased significantly by 7.1% over the past month...

If you are weighing what to do about Royal Caribbean Cruises stock right now, you are not alone. The share price has been a livewire, delivering a 106.3% jump over the past year and a remarkable 735.6% over the last three years, making those pandemic-era lows seem like ancient history. Even in the short term, Royal Caribbean is still riding some waves, up 4.5% in the last week but down 2.2% over the past month, as investors digest changing market sentiment and industry headlines. Momentum...

Despite an already strong run, Perimeter Solutions, Inc. ( NYSE:PRM ) shares have been powering on, with a gain of 26...

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

If you have been watching 3M lately and wondering whether now is the right time to make a move with its stock, you are in good company. The share price has picked up some positive momentum, rising 1.0% over the past week and 3.0% over the last month. Even more impressive, the stock is currently 20.2% higher so far this year, and it is up a solid 21.0% over the past twelve months. These numbers certainly catch the eye, especially for anyone who remembers 3M’s challenges in previous years. With...

If you own EMCOR Group stock or are thinking of getting in, you’re likely wondering where this impressive run goes from here. The past few years have been nothing short of a rocket ride for EMCOR Group, with the stock up 727.4% over the last five years and 409.5% in just the past three. Even after that incredible surge, 2024 has brought another wave of strong performance, with shares logging a 33.1% gain since the start of the year. The last 30 days have seen a slight pullback of 4.1%, but...

Despite an already strong run, Optical Cable Corporation ( NASDAQ:OCC ) shares have been powering on, with a gain of...

Teekay Corporation Ltd.'s ( NYSE:TK ) price-to-earnings (or "P/E") ratio of 8.7x might make it look like a strong buy...

Avis Budget Group, Inc. ( NASDAQ:CAR ) shares have retraced a considerable 26% in the last month, reversing a fair...

You may think that with a price-to-sales (or "P/S") ratio of 1.3x AngioDynamics, Inc. ( NASDAQ:ANGO ) is a stock worth...

Jin Medical International Ltd. ( NASDAQ:ZJYL ) shares have had a really impressive month, gaining 31% after a shaky...

Despite an already strong run, Deswell Industries, Inc. ( NASDAQ:DSWL ) shares have been powering on, with a gain of...

There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll want...

Gaxos.ai (NASDAQ: GXAI), the small but ambitious AI company, has just unveiled a new weapon in its arsenal: Art-Gen.AI. While many investors know Gaxos for its dual focus on AI in gaming and health, this new platform catapults the company into the booming world of generative content creation, a market projected to reach hundreds of billions in annual revenue.

Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 49% gain in the last month...

ZIM Integrated Shipping Services ( NYSE:ZIM ) Second Quarter 2025 Results Key Financial Results Revenue: US$1.64b (down...

Royalty Pharma (RPRX) recently acquired a royalty interest in Amgen's Imdelltra, a move that may have added confidence to investors, contributing to the company's 11% share price increase over the last quarter. This acquisition, along with its royalty sharing arrangements and the drug's anticipated market success, illustrates Royalty Pharma’s strategic business expansion. Concurrently, it saw enhancements in its board composition with new appointments, which might have played a beneficial...

Abercrombie & Fitch (ANF) recently entered a multi-year partnership with the NFL as the Official Fashion Partner, launching the "Style Concierge" campaign featuring notable players. This major collaboration aimed to redefine fan style and likely contributed to ANF's 28% price rise over the last quarter. The campaign, complemented by strategic activations and limited-edition apparel, increased brand visibility. Additionally, the company's aggressive share repurchase activities and recent...